|
Alias names |
|
Bcl2 modifying factor isoform 3
|
|
Sequence |
|
MASMTGGQQM GRGSHMEPSQ CVEELEDDVF QPEDGEPVTQ PGSLLSADLF AQSLLDCPLS RLQLFPLTHC CGPGLRPTSQ EDKATQTLSP ASPSQGVMLP CGVTEEPQRL FYAPAEPKSC VVADPPLPAQ PCFEWRREQE RGRP
|
|
Concentration |
|
1 mg/ml (determined by Bradford assay)
|
|
Substrate/Buffer |
|
Liquid. In 20 mM Tris-HCl buffer (pH 7.5) containing, 1mM DTT, 10% glycerol. Endotoxin Level: < 1.0 EU per 1 μg of protein (determined by LAL method)
|
|
Storage |
|
Can be stored at +4°C short term (1-2 weeks). For long term storage, aliquot and store at -20°C or -70°C. Avoid repeated freezing and thawing cycles
|
|
References |
|
Morales AA., et al. (2004). Leukemia. 18(1):41-7
Chen L., et al. (2005). Mol Cell. 17(3):393-403
|
|
Contents/Specifications |
|
Recombinant human BMF, fused to T7-tag at N-terminus, was expressed in E.coli and purified by using conventional chromatography.
|
|
Notes |
|
Bcl2 modifying factor, also known as BMF belongs to the Bcl2 protein family of apoptosis mediators. Bmf is constitutively expressed in many tissues. This protein contains a single Bcl2 homology domain 3 (BH3), and has been shown to bind Bcl2 proteins and function as an apoptotic activator. Also, BMF is a key molecule for histone deacetylase (HDAC) inhibitors which alters the balance between acetylation and deacetylation, significantly increasing histone acetylation, while strongly inducing apoptosis in a variety of cancer cell types.
|